Corpus Intelligence IC Memo — MEDICAL ARTS HOSPITAL 2026-04-26 15:27 UTC
IC Memo — MEDICAL ARTS HOSPITAL
Investment Committee Memorandum | TX | 21 beds | Grade D | EBITDA uplift $919K
🛡️ Public data only — no PHI permitted on this instance.
Investment Committee Memorandum

MEDICAL ARTS HOSPITAL

CCN 450489 | DAWSON, TX | 21 beds | April 26, 2026
EBITDA BridgeData Room
D
Investability

1. Target Overview & Investment Thesis

MEDICAL ARTS HOSPITAL is a 21-bed community hospital in DAWSON, TX with $12.4M in net patient revenue and a -61.7% operating margin. The hospital serves a payer mix of 31.7% Medicare, 0.0% Medicaid, and 68.3% commercial.

Thesis: Turnaround. Our ML models identify $919K in annual EBITDA improvement potential from RCM optimization across 5 levers, lifting margin from -61.7% to -54.3% (+739bps).

Net Revenue HCRIS$12.4M
Current EBITDA COMPUTED$-7.7M
Operating Margin COMPUTED-61.7%
Occupancy HCRIS13.1%
Revenue / Bed COMPUTED$593K
Net-to-Gross HCRIS38.6%
Distress Probability MLnan%

2. Market Context & Competitive Position

583
TX Hospitals
-0.7%
State Median Margin
228
Comparable Hospitals

TX has 583 Medicare-certified hospitals with a median operating margin of -0.7%. The target's margin of -61.7% places it below the state median. Among 228 size-comparable peers (10-42 beds), the median margin is -8.9%. The target's below-peer margin suggests operational improvement opportunity.

3. RCM Performance Analysis — Comparable Hospitals

Comps selected by bed count (10-42), prioritizing same-state peers. 228 hospitals in the comp set.

HospitalStateBedsRevenueMargin
MEDICAL ARTS HOSPITAL (Target)TX21$12.4M-61.7%
WISE HEALTH SYSTEM - PARKWAYTX36$361.0M-15.5%
CORYELL MEMORIAL HOSPITALTX25$305.9M-1.5%
TEXAS ORTHOPEDIC HOSPITATX42$237.8M46.3%
METHODIST HOSPITAL FOR SURGERYTX32$178.4M22.8%
TEXAS SPINE AND JOINT HOSPITALTX20$147.3M30.3%
NORTH CENTRAL SURGICAL HOSPITATX24$143.6M32.0%
SCOTT AND WHITE HOSPITAL TAYLOTX25$139.7M-47.5%
BAYLOR SURGICAL HOSPITAL AT FOTX30$136.0M14.8%

4. Predicted Improvement Opportunities

Improvement targets set at P75 of comparable peers with 60% gap closure assumption. Coefficients calibrated to published research bands. Total EBITDA uplift: $919K (739bps margin improvement).

LeverCurrentTargetEBITDA ImpactMarginRamp
Net Collection Rate93.5%97.0%$261K+210bp18mo
Cost to Collect4.5%2.5%$249K+200bp12mo
Denial Rate Reduction12.0%6.5%$248K+199bp12mo
A/R Days Reduction5200.0%3800.0%$151K+122bp9mo
Clean Claim Rate88.0%96.0%$10K+8bp6mo

5. EBITDA Bridge

Net Collection Rate
$261K
Cost to Collect
$249K
Denial Rate Reduction
$248K
A/R Days Reduction
$151K
Clean Claim Rate
$10K
Total EBITDA Uplift$919K
Current EBITDA$-7.7M
+ RCM Uplift+$919K
Pro Forma EBITDA$-6.8M
Current Margin-61.7%
Pro Forma Margin-54.3%
WC Released (1x)$478K

6. Returns Analysis — Scenario Matrix

5-year hold, 5.5x leverage, 3% organic growth, 10%/yr debt paydown. Base case uses 100% of predicted RCM uplift. Bull case: 130% uplift at lower entry. Bear case: 50% uplift at higher entry.

ScenarioEntryExitEquity InEquity OutMOICIRR
Base Case10.0x10.0x$-11.8M$-41.5M0.00x-100.0%
Base (11x exit)10.0x11.0x$-11.8M$-49.5M0.00x-100.0%
Bull Case9.0x11.0x$-10.6M$-50.3M0.00x-100.0%
Bull (12x exit)9.0x12.0x$-10.6M$-58.0M0.00x-100.0%
Bear Case11.0x10.0x$-13.0M$-42.3M0.00x-100.0%
Bear (11x exit)11.0x11.0x$-13.0M$-50.7M0.00x-100.0%

7. Key Risks & Mitigants

SeverityRisk FactorMitigant
HighNegative operating marginRCM uplift bridge shows clear path to profitability; working capital release provides near-term cash cushion
MediumLow occupancyAt 13.1%, fixed costs are spread over fewer patient days. Mitigant: volume growth is an additional upside lever not modeled in base case

8. Data Sources & Methodology Appendix

Data Sources

  • CMS HCRIS Cost Reports (Medicare-certified hospitals)
  • CMS Medicare Utilization (DRG-level volumes)
  • CMS Chronic Conditions (county-level disease prevalence)
  • HCRIS multi-year trend data (financial time series)

Comparable Selection

  • 228 hospitals with 10-42 beds
  • Same-state prioritization (n=229)
  • Comp margins: P25=-39.5% / P50=-8.9% / P75=9.4%

Bridge Methodology

  • Targets: P75 of comparable peers (60% gap closure)
  • Denial: avoidable share = 35% of delta × NPR
  • AR: bad debt coefficient = $0.65 per day per $1K NPR
  • NCR: 60% coefficient on collection rate improvement
  • CDI: 0.75% of Medicare revenue per 0.01 CMI point

Returns Assumptions

  • Leverage: 5.5x entry (84.6% debt / 15.4% equity)
  • Organic growth: 3% annual EBITDA growth
  • Debt paydown: 10% of principal per year
  • Hold period: 5 years

Generated by SeekingChartis on April 26, 2026. All predictions use public data only. Confidence intervals calibrated via split conformal prediction (90% coverage target). This memo is for informational purposes and does not constitute investment advice.